PubMed Health⌕ Search

Biomedical subjects

D Tulchinsky

Publications and source records attributed to D Tulchinsky.

At least 37 records · Page 2Linked to original sources

Endocrine assessments of fetal-placental well-being.

Continued advances in perinatology and neonatology and the introduction of biochemical and biophysical methods for evaluating pregnancy have substantially improved the perinatal outcome. Biochemical evaluation of placental function appears to play an important role in the management of complications of early and late pregnancy. Improvements in methodology and increased experience in the application of the various techniques have enhanced our ability to diagnose normal and abnormal pregnancy. The various new placental proteins recently described have not yet found their place in modern obstetrics and thus far they do not seem to offer distinct advantage over more established methods for assessing fetoplacental function.

Chorionic Gonadotropin↗

Glucocorticoid metabolism in human placenta, decidua, myometrium and fetal membranes.

The metabolism of cortisone (E) and cortisol (F) by human placenta, decidua, myometrium, chorion and amnion during pregnancy was studied in vitro. Early pregnancy, midpregnancy and term placentae metabolized F efficiently yielding E as the major product. The capacity of the placenta to inactivate F to E was observed as early as the 8th week of pregnancy and there was a significantly higher (P less than 0.001) net production of E in early pregnancy placenta than in term placenta. In contrast to the placenta, midpregnancy and term decidua metabolized mainly E to F with a net production of F. Term chorion demonstrated an equal degree of oxidative and reductive glucocorticoid metabolism while term amnion and myometrium had negligible metabolic activity. Thus the net production of F from E by the decidual membrane unit is due to metabolic activity in the decidua as early as the 13th week of pregnancy and not to activity in the fetal membranes.

Cortisone↗

Endometrial hyperplasia in women on cyclic or continuous estrogen regimens.

Twenty-five symptomatic postmenopausal women with an intact uterus were assigned in random double-blind fashion to receive 0.625 mg of conjugated estrogens on either a cyclic (3 weeks on, 1 week off) or continuous (daily) basis. The incidence of endometrial hyperplasia as demonstrated by screening biopsies at 6 and 12 months of therapy was 4.5 per 100 woman-months in the cyclic group and 3.7 per 100 woman-months in the continuous group (a difference not statistically significant). Thus, in this study, cyclic therapy was found to offer no advantage over continuous therapy. In our opinion, the rate of hyperplasia development in both groups unacceptably high, and efforts must be directed at reducing its incidence primarily.

Biopsy↗

Determinations of endogenous immunoreactive luteinizing hormone-releasing hormone in human plasma.

A specific and sensitive RIA was developed for measuring immunoreactive LHRH (IR-LHRH) in methanol acid-extracted human plasma. Heparinized blood samples were obtained from normal adult women and men, and the plasma was extracted with methanol, acidified, lyophilized, and stored at -20 C until assayed for LHRH. The lowest detectable levels of IR-LHRH in 1.0-3.5 ml methanol acid-extracted plasma ranged from 0.975-1.95 pg/assay tube, and recovery of synthetic LHRH from plasma averaged 88.6 +/- 2.4% (SE). Gel chromatographic separation analysis revealed comparable elution peaks for endogenous, tritiated, and synthetic LHRH. The plasma extract was also effective in evoking the release of LH and FSH in vitro using isolated rat hemipituitaries. IR-LHRH levels in human peripheral plasma rose 50-fold within seconds after an iv bolus injection of 100 micrograms synthetic LHRH with a return to baseline within 60 min. When the pattern of IR-LHRH secretion in peripheral plasma was studied, episodes of IR-LHRH rise were observed approximately every 60 min in both men and women. The physiochemical and biochemical properties of IR-LHRH suggest that it is an authentic LHRH. The presence of pulses of IR-LHRH suggests that its concentration in peripheral blood reflects changes in levels in the pituitary portal blood.

Adult↗

Objective evidence that placebo and oral medroxyprogesterone acetate therapy diminish menopausal vasomotor flushes.

The vasomotor flush (VMF) is the most common reason for menopausal women to seek hormonal therapy, but the evaluation of therapeutic regimens has been hampered by the observation that placebo therapy can decrease VMF and, until recently, by a lack of objective criteria of measurement of the VMF. Using the objective criteria of temperature elevations (TEs) and luteinizing hormone (LH) pulses, we evaluated the effect of placebo and medroxyprogesterone acetate (MPA) on VMF. MPA and possibly also placebo were found to reduce not only the subjectively noted VMF but also the frequency of TEs recorded. In addition, MPA, but not placebo, significantly reduced the frequency and amplitude of LH pulses. Possible mechanisms of action of MPA and placebo therapy are discussed.

Body Temperature↗

Relationship among estrogen-induced psychophysiological changes in hypogonadal women.

Estrogen treatment of 16 hypogonadal women showed lessening of gonadotrophins, vasomotor symptoms, psychometrically measured aggression, and average sleep latency, but more Rapid Eye Movement sleep in a 100-day cross-over, double-blind comparison with placebo treatment. Of eight insomniac subjects, four showed decreased, but four showed increased insomnia scores and sleep latencies. Clinical rank of psychological intactness correlated with sleep latency and with total sleep time during the estrogen condition. Although estrogen altered both physiological and psychological states, such effects were characterized by different time courses and different degrees of consistency among the subjects.

Affect↗

Episodic secretion of human chorionic gonadotropin in early pregnancy.

The serum concentration of human chorionic gonadotropin (hCG) was measured at 10- to 60-minute intervals for 4-24 hours in 5 women at 5-8 weeks of pregnancy. hCG was found to be secreted episodically with pulses observed every 2-4 hours. The episodic secretion of hCG may have important implications to our understanding of both normal and abnormal reproduction.

Chorionic Gonadotropin↗

Plasma estriol and its conjugates following oral and vaginal administration of estriol to postmenopausal women: correlations with gonadotropin levels.

A study was designed to compared the metabolic fate and the biologic effects of 4 mg of estriol (E3) administered either orally or vaginally to six postmenopausal women. Blood samples were collected every hour for 6 hours and five different estriol fractions as well as gonadotropins were measured. Vaginal E3 administration resulted in a decline of 45% in luteinizing hormone (LH) levels and 17% in follicle-stimulating hormone (FSH) levels at 6 hours after treatment (p < 0.05). In contrast, the administration of 4 mg of E3 orally did not produce a decline of LH and FSH, despite the fact that the serum levels of E3-3-sulfate, E3-3-sulfate-16-glucosiduronate, estriol-3-glucosiduronate, and estriol-16-glucosiduronate were all fourfold to 24-fold higher after oral administration than after vaginal estriol administration. However, since the levels of unconjugated E3 were higher after the vaginal than after the oral administration of estriol, we conclude that only unconjugated E3 suppresses gonadotropins.

Administration, Oral↗

Suppression of prolactin secretion in normal young women by 2-hydroxyestrone.

The nonuterotropic natural estrogen 2-hydroxyestrone administered to normal young women results in a prompt and profound suppression of serum prolactin in most of the subjects. With the exception of dopamine, this is the only endogenous material known to strongly inhibit prolactin secretion, and its action suggests that the physiological regulation of prolactin by estrogens in the human is dual in nature, consisting of stimulation by estradiol and inhibition by its catechol estrogen metabolite.

Adult↗

Oral medroxyprogesterone in the treatment of postmenopausal symptoms.

A double-blind crossover study was designed to compare the effects of placebo and medroxyprogesterone acetate, 20 mg, on vasomotor flushes and blood hormones in 27 postmenopausal women. In women receiving placebo, vasomotor flushes were decreased by 25.9% during the last four weeks of treatment compared with baseline, and a further decrease of 34.5% was achieved by the last four weeks after patients were given medroxyprogesterone. In women who initially took medroxyprogesterone, there a 73.9% decline by the last four weeks in the number of vasomotor flushes. However, when these women were given placebo, an immediate worsening of their symptoms occurred. The drug produced a decline of 27% and 29% in serum levels of follicle-stimulating hormone and luteinizing hormone, respectively, while the serum prolactin level rose slightly. Thus, medroxyprogesterone can be used to treat the vasomotor flushes of postmenopausal women when estrogen use is undesirable.

Administration, Oral↗

Direct evidence of sudden rise in fetal corticoids late in human gestation.

Glucocorticoids accelerate fetal lung maturation in all mammals studied, and in some species, such as goat and sheep, concentrations of fetal cortisol increase sharply before term, bringing about a train of events leading to parturition. Studies of cortisol in the umbilical cord blood have revealed no such increase at the end of human pregnancy. But information obtained in that way is difficult to interpret because much of the fetal cortisol is of maternal origin and its concentration, if sampled at delivery, is affected by maternal stress. These problems can be avoided to some extent by studying other fetal corticoids. Corticosterone sulphate (once called compound B, and abbreviated to BS) is produced by fetal adrenal glands and is present in greater concentrations in human fetal plasma than in maternal plasma. It is hydrolysed by the placental sulphatases and is a poor substrate for for placental 11 beta- hydroxysteroid dehydrogenase. We report here confirmation that the bulk of maternal BS originates from the fetus, and that its concentration increases suddenly at term.

Adrenal Glands↗

Abnormal adrenal responses to adrenocorticotropic hormone in hyperandrogenic women.

The plasma concentrations of testosterone (T), dehydroepiandrosterone (D), androstenedione (A), pregnenolone (delta 5P), progesterone (P), 17-hydroxypregnenolone (17-delta 5P), 17-hydroxyprogesterone (17-P), 11-deoxycortisol (S), and cortisol (F) were measured before, and 30 and 60 minutes after, a bolus intravenous injection of 25 units of adrenocorticotropic hormone (ACTH) in nine normal women and in fifteen patients with a variety of manifestations of androgen excess. Patients with androgen excess demonstrated significantly higher mean baseline levels of T, D, A, delta 5P, 17-delta 5P, and 17-P. After a bolus intravenous injection of 25 units of ACTH, higher-than-normal increments were noted for the following steroids: delta 5P (one patient), 17-delta 5P (one patient), D (two patients), P (one patients), 17-P (two patients), and S (two patients). Following ACTH injections, the ratios of increments in plasma steroid pairs were computed to estimate the efficiency of several adrenal enzymes, and evidence suggesting partial deficiency of 3 beta-hydroxysteroid dehydrogenase delta 4-5 isomerase (five patients) and 11 beta-hydroxylase (five patients) was found. In addition, 6 of the 15 patients with androgen excess exhibited an abnormally high increment in D relative to the increment in F. The data show that apparent abnormalities in adrenal steroid biosynthesis are a frequent occurrence in patients with hyperandrogenism.

17-alpha-Hydroxypregnenolone↗

Characterization of hyperandrogenism with insulin-resistant diabetes type A.

The characterization of the hyperandrogenism of two sisters with type A insulin-resistant diabetes and hirsutism is presented. Testosterone (T) and androstenedione levels were elevated in peripheral serum. These were not markedly affected by infusion of adrenocorticotropic hormone. In patient 1 glucocorticoid suppression decreased T levels by 50% and androstenedione levels by 30% but had no effect on them in patient 2. Estrogen-progestin suppression markedly reduced testosterone levels in both patients. The blood production of T in patient 1 was 0.8 mg/day and in patient 2 was 4.5 mg/day, both of which are elevated. Selective venous catheterization in patient 2 revealed markedly elevated testosterone levels in the ovarian veins, and polycystic ovaries were found at subsequent laparotomy. These endocrine studies have shown that the source of excessive testosterone in these patients is excessive production by the ovaries, and it can be suppressed by oral contraceptives.

Adolescent↗

The use of constant infusion of unlabeled dehydroepiandrosterone for the assessment of its metabolic clearance rate, its half-life, and its conversion into estrogens.

We have exploited the feasibility of utilizing constant infusion of unlabeled dehydroepiandrosterone (DHEA) for calculating its MCR, its half-life (t1/2), and its conversion ratio into estrogens. In nonpregnant women, results obtained by infusion of unlabeled DHEA were similar to those obtained by the infusion of either labeled steroid or a mixture of labeled and unlabeled steroid. An increase of 3-fold in the infusion rate did not change any of these results, indicating that enzyme availability was not a limiting step in the production of estradiol (E2) from DHEA. When compared to the nonpregnancy state, term pregnancy was not associated with a change in plasma DHEA concentrations, but the MCR of DHEA of 76.8 +/- 18.8 (SE) liters/kg.day was 2.5-fold higher and the t1/2 of 22.5 +/- 3.6 min was 2-fold lower. The conversion ratio of DHEA into E2 increased during pregnancy by 500-fold, and DHEA contributed 9% of maternal circulating E2. In the first postpartum day, the MCR of DHEA and its t1/2 were not significantly different from those of term pregnancy, suggesting that the increased MCR of DHEA in pregnancy was not solely due to increased clearance of DHEA by the placenta.

Adult↗

Suppression of prolactin and gonadotropin secretion in post-menopausal women by 2-hydroxyestrone.

An infusion of 2-hydroxyestrone given to estrogen primed post-menopausal women resulted in a rapid and total suppression of serum prolactin. Serum LH responded with an initial rise followed by a 30% decrease below baseline values. Serum FSH exhibited a significant suppression below preinfusion levels. The catechol estrogen had no effect on serum LH, FSH and PRL in post-menopausal women who were not pretreated with estrogens. This impact of 2-hydroxyestrone on pituitary hormone secretion provides for the physiological role of this non-uterotropic estrogen in the neuroendocrine mechanisms of the human.

Estrone↗

The intraovarian sites of androgen and estrogen formation in women with normal and hyperandrogenic ovaries as judged by in vitro experiments.

The status of oocytes, the follicular fluid concentrations of steroids, and the in vitro steroidogenic capacities of stromal tissue, thecal tissue, and granulosa cells from a 15-yr-old girl with primary amenorrhea, ovarian hyperandrogenism, insulin-resistant diabetes mellitus, and acanthosis nigricans were compared to those from normal adult human ovaries. Most oocytes (95%) in the antral follicles recovered from the hyperandrogenic ovaries were degenerative, and the antral fluid levels of testosterone were 30- to 200-fold higher than those in normal ovaries. Granulosa cells from the hyperandrogenic ovaries produced mainly estradiol as did those from normal healthy follicles. The thecal tissues produced 2- to 6-fold more androgen than similar tissues from normal ovaries. However, the stroma from the hyperandrogenic ovaries produced 49- to 250-fold more testosterone than that generated by normal tissues. These data suggest that the removal of stromal tissue as well as follicular tissue from patients with certain types of hyperandrogenism may sometimes contribute to a reduction in androgen secretion.

Adolescent↗